Essa Pharma Stock Price, News & Analysis

ESSA Pharma (NASDAQ: EPIX) has announced a definitive agreement to be acquired by XenoTherapeutics, with financing from XOMA Royalty Corporation (NASDAQ: XOMA). The all-cash transaction will provide EPIX shareholders with approximately $1.91 per common share, plus one non-transferable contingent value right (CVR) worth up to $0.06 per share payable within 18 months post-closing.

The transaction, expected to close in second half of 2025, requires approval from 66⅔% of ESSA shareholders and securityholders. The agreement includes a $2.5 million termination fee and customary deal-protection provisions. ESSA's board unanimously approved the transaction, with directors and senior officers, holding 2.23% of shares, agreeing to vote in favor.

ESSA Pharma (NASDAQ: EPIX) reported its fiscal Q2 2025 financial results, highlighting ongoing efforts to evaluate strategic options after discontinuing its prostate cancer clinical trials. The company recorded a net loss of $6.4 million, improved from $9.0 million in Q2 2024. R&D expenses decreased to $3.5 million from $6.2 million, while G&A expenses reduced to $3.9 million from $4.3 million year-over-year.

The company maintains a strong financial position with $113.9 million in cash and short-term investments and $113.5 million in net working capital as of March 31, 2025. ESSA is exploring various strategic alternatives, including potential mergers, acquisitions, or business combinations, while implementing cost reductions and headcount adjustments.

ESSA Pharma Inc. (NASDAQ: EPIX) held its Annual General Meeting of Shareholders on March 5, 2025. The company, which previously focused on developing prostate cancer therapies before discontinuing its clinical trials and development programs, announced key shareholder votes.

Shareholders approved setting the board size at seven directors and re-elected David R. Parkinson, Richard M. Glickman, Franklin M. Berger, Scott Requadt, Marella Thorell, Alex Martin, and Sandy Zweifach. Additional approvals included the re-appointment of Davidson & Company LLP as auditors and a non-binding advisory vote on executive compensation.

ESSA Pharma (NASDAQ: EPIX) reported financial results for Q1 2025 ended December 31, 2024. Following the termination of masofaniten clinical trials, the company is exploring strategic options to maximize shareholder value, including potential merger, asset sale, or dissolution.

Key financial highlights: Net loss increased to $8.5 million compared to $6.0 million in Q1 2023. R&D expenses were $5.5 million vs $5.4 million year-over-year, while G&A expenses rose to $4.2 million from $2.2 million. The company maintains a strong financial position with $120.6 million in cash reserves and short-term investments, and $118.8 million in net working capital.

The company has 44,388,550 common shares outstanding and 2,920,000 common shares issuable through prefunded warrants at $0.0001 exercise price.

ESSA Pharma (NASDAQ: EPIX) has announced the termination of all clinical trials for masofaniten following disappointing interim analysis results of its Phase 2 combination study with enzalutamide for prostate cancer treatment. The company has initiated a strategic review process to maximize shareholder value, which may include merger, acquisition, or liquidation options.

Financial highlights for fiscal year 2024 include a net loss of $28.5 million, compared to $26.6 million in 2023. R&D expenditures were $21.2 million, while G&A expenses increased to $13.2 million from $10.8 million in 2023. The company maintains a strong financial position with $126.8 million in cash reserves and $124.3 million in net working capital as of September 30, 2024.

ESSA Pharma announced the termination of its Phase 2 clinical trial evaluating masofaniten combined with enzalutamide in metastatic castration-resistant prostate cancer patients. The decision came after a futility analysis showed the enzalutamide control arm performing better than historical controls and similar to the combination therapy, making it unlikely to achieve the primary endpoint. All additional clinical studies with masofaniten will be terminated. The company reported $126.8 million in cash reserves and $124.3 million in net working capital as of September 30, 2024. Management will initiate a strategic review process to maximize shareholder value.

ESSA Pharma presented updated Phase 1/2 clinical data for masofaniten (EPI-7386) in combination with enzalutamide at the 2024 ESMO Congress. The study focused on patients with metastatic castration-resistant prostate cancer (mCRPC). Key findings include:

- 88% of patients achieved PSA90
- 69% achieved PSA90 in less than 90 days
- 63% achieved PSA <0.2ng/mL
- After 15.2 months, median time to PSA progression and radiographic progression-free survival not yet reached
- Combination well-tolerated with durable PSA reductions
- Phase 2 dose expansion ongoing at RP2CDs of masofaniten 600 mg BID with enzalutamide 160 mg QD

The data suggests favorable outcomes compared to historical single-agent enzalutamide treatment in mCRPC patients.

ESSA Pharma (NASDAQ: EPIX), a clinical-stage pharmaceutical company focused on developing novel therapies for prostate cancer treatment, has announced its participation in the 2024 Cantor Global Healthcare Conference. The company will present on September 18, 2024, at 9:10 a.m. ET in New York, NY.

Key executives participating in a fireside chat include David R. Parkinson (President and CEO), Peter Virsik (COO and EVP), and David S. Wood (CFO). A live webcast of the event will be available on ESSA's website in the Investors/Events & Presentations section, and will remain archived for 90 days post-event.

ESSA Pharma (NASDAQ: EPIX) provided a corporate update and reported financial results for Q3 2024. Key highlights include:

1. On track to report updated Phase 1 masofaniten plus enzalutamide data in mCRPC patients in H2 2024.

2. Phase 1b monotherapy results expected in H2 2024.

3. Phase 2 dose expansion ongoing; enrollment completion projected for Q1 2025, with preliminary data expected mid-2025.

4. Q3 2024 net loss of $7.2 million, compared to $7.3 million in Q3 2023.

5. R&D expenses decreased to $5.5 million from $6.3 million year-over-year.

6. Cash reserves of $130.7 million as of June 30, 2024, sufficient to fund operations beyond 2025.